Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Collegium Pharma (COLL) Reports In-Line Q4 EPS; Offers FY23 Revenue Guidance
February 23, 2023 4:29 PM ESTCollegium Pharma (NASDAQ: COLL) reported Q4 EPS of $1.09, in-line with the analyst estimate of $1.09. Revenue for the quarter came in at $129.6 million versus the consensus estimate of $125.2 million.
GUIDANCE:
Collegium Pharma sees FY2023 revenue of $565-580 million, versus the consensus of... More
